NYSE:PFE
PFIZER INC
A global biopharmaceutical giant delivering innovative medicines and vaccines with a diversified portfolio spanning human health, animal health, and consumer care segments.
Key Metrics
Investment Thesis
Bull Case
Investors should consider Pfizer for its attractive dividend yield supported by robust operating cash flow of $11.70B and a diversified pipeline that mitigates reliance on any single product. The stock offers value through potential share buybacks funded by excess liquidity and the strategic repositioning toward high-value oncology and immunology assets.
Bear Case
Bearish cases highlight the risk of declining sales as blockbuster vaccines lose patent exclusivity, which could compress margins given the heavy investment in general and administrative expenses of $13.79B. Additionally, the significant debt load relative to equity and potential for further M&A integration challenges pose risks to future earnings stability.
About PFIZER INC
Pfizer Inc. is a global biopharmaceutical leader delivering innovative medicines and vaccines across human health, animal health, and consumer care markets. With a diverse portfolio including renowned brands like Pfizer and Comirnaty, the company serves patients worldwide while managing a significant pipeline of late-stage clinical assets. The firm operates through integrated segments focusing on immunology, oncology, virology, and rare diseases to address critical unmet medical needs.
Analysis
Management Discussion
Pfizer demonstrated resilience with $62.58B in revenue and $7.81B net profit in 2025, recovering strongly from the sharp normalization following its peak pandemic earnings in 2022. The company generated substantial free cash flow to fund $6.93B in acquisitions and maintain a healthy balance sheet with $1.20B in ending cash, though debt levels remain elevated at $61.64B.
Industry Overview
The global pharmaceutical industry is characterized by high R&D costs, strict regulatory oversight, and rapid technological shifts toward personalized medicine and gene therapies. Pfizer operates in a competitive landscape where patent cliffs are common, forcing companies to continuously innovate or acquire new assets to maintain revenue growth and market share.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $100.33B | $58.50B | $63.63B | $62.58B |
| Cost of Revenue | $34.34B | $24.95B | $17.85B | $16.07B |
| Gross Profit | $65.99B | $33.54B | $45.78B | $46.51B |
| Operating Expenses | $31.26B | $32.48B | $37.75B | $38.99B |
| Operating Income | $34.73B | $1.06B | $8.02B | $7.52B |
| G&A | $13.68B | $14.77B | $14.73B | $13.79B |
| Stock-Based Comp | $872.0M | $525.0M | $877.0M | $799.0M |
| D&A | $5.06B | $6.29B | $7.01B | $6.59B |
| Amortization | $3.60B | $4.70B | $5.30B | — |
| Other OpEx | $17.58B | $17.71B | $23.02B | $25.20B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1.24B | $2.21B | $3.09B | $2.67B |
| Interest Income | $251.0M | $1.62B | $545.0M | $603.0M |
| Pre-Tax Income | $34.73B | $1.06B | $8.02B | $7.52B |
| Income Tax | $3.33B | $-1.11B | $-28.0M | $-266.0M |
| Continuing Ops | $31.40B | $2.17B | $8.05B | $7.79B |
| Discontinued Ops | $6.0M | $-15.0M | $11.0M | $25.0M |
| Net Income | $31.41B | $2.16B | $8.06B | $7.81B |
| Minority Interest | $35.0M | $39.0M | $31.0M | $41.0M |
| Net to Common | $31.37B | $2.12B | $8.03B | $7.77B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $51.26B | $43.33B | $50.36B | $42.90B |
| Cash & Equivalents | $416.0M | $2.85B | $1.04B | $1.14B |
| Accounts Receivable | $10.95B | $11.18B | $11.46B | $11.87B |
| Inventory | $8.98B | $10.19B | $10.85B | $10.65B |
| Other Current Assets | $30.91B | $19.11B | $27.00B | $19.23B |
| Long-Term Assets | $145.95B | $183.17B | $163.04B | $165.26B |
| PP&E (Net) | $16.27B | $18.94B | $18.39B | $19.32B |
| Intangibles | $43.37B | $64.90B | $55.41B | $53.73B |
| Goodwill | $51.38B | $67.78B | $68.53B | $71.26B |
| Operating Leases | $3.00B | $2.92B | $2.29B | $2.21B |
| LT Investments | $15.07B | $15.37B | $2.23B | — |
| Other LT Assets | $5.82B | $1.62B | $15.97B | $18.50B |
| Total Assets | $197.21B | $226.50B | $213.40B | $208.16B |
| Current Liabilities | $42.14B | $47.79B | $42.99B | $36.98B |
| Accounts Payable | $6.81B | $6.71B | $5.63B | $5.24B |
| Current Debt | $2.56B | $2.25B | $3.75B | $3.00B |
| Current Leases | $620.0M | $527.0M | $356.0M | $330.0M |
| Deferred Revenue | $2.52B | $2.70B | $1.51B | $784.0M |
| Other Current Liab | $27.33B | $33.23B | $29.31B | $25.19B |
| Long-Term Liabilities | $59.15B | $89.42B | $81.90B | $84.40B |
| Long-Term Debt | $32.88B | $61.54B | $57.41B | $61.64B |
| LT Operating Leases | $2.60B | $2.63B | $2.29B | $2.29B |
| Other LT Liab | $23.67B | $17.29B | $19.76B | $20.47B |
| Total Liabilities | $101.29B | $137.21B | $124.90B | $121.39B |
| Shareholders' Equity | $95.92B | $89.29B | $88.50B | $86.78B |
| Paid-In Capital | $91.80B | $92.63B | $93.60B | $94.47B |
| Retained Earnings | $125.66B | $118.35B | $116.72B | $114.61B |
| AOCI | $-8.30B | $-7.96B | $-7.84B | $-8.07B |
| Treasury Stock | $113.97B | $114.49B | — | — |
| Total L&E | $197.21B | $226.50B | $213.40B | $208.16B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $31.41B | $2.16B | $8.06B | $7.81B |
| Non-Cash Adjustments | $-4.99B | $7.04B | $12.58B | $12.42B |
| Working Capital Changes | $2.85B | $-502.0M | $-7.90B | $-8.53B |
| Cash from Operations | $29.27B | $8.70B | $12.74B | $11.70B |
| Capital Expenditures | $3.24B | $3.91B | $2.91B | $2.63B |
| Cash from Investing | $-15.78B | $-32.28B | $2.65B | $-1.35B |
| Debt Issuances | $0 | $30.83B | $0 | $9.68B |
| Debt Repayments | $3.30B | $2.57B | $2.25B | $6.76B |
| Share Buybacks | $2.00B | $0 | $0 | — |
| Cash from Financing | $-14.83B | $26.07B | $-17.14B | $-10.30B |
| FX Effect | $-165.0M | $-40.0M | $-66.0M | $41.0M |
| Net Change in Cash | $-1.51B | $2.45B | $-1.81B | $91.0M |
| Beginning Cash | $1.98B | $468.0M | $2.92B | $1.11B |
| Ending Cash | $468.0M | $2.92B | $1.11B | $1.20B |
Frequently Asked Questions
How does PFIZER INC make money?
The company's revenue is driven by four primary pillars: Vaccines (including COVID-19 products and influenza), Innovative Medicines (oncology, immunology, and virology therapies), Biologics & Biosimilars, and Consumer Health. Financials reflect strong cash generation from operations ($11.70B) supporting these segments, while significant goodwill ($71.26B) indicates a history of strategic M&A integrating diverse therapeutic areas.
What are the main risks for PFE?
Revenue concentration risk tied to the expiration of key patent protections for high-volume products like Comirnaty, potential regulatory headwinds from global health authorities, and volatility in net income driven by large one-time charges or acquisition integration costs as seen in recent years.
What is PFE's competitive advantage?
First-mover advantage in vaccine distribution networks, a robust late-stage pipeline extending beyond its COVID-19 franchise, and superior manufacturing scale that provides cost leadership in biologics production.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.